financetom
Business
financetom
/
Business
/
Mindtree to continue as separate entity, new CEO to be announced soon, says L&T
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mindtree to continue as separate entity, new CEO to be announced soon, says L&T
Jul 8, 2019 9:13 AM

Following its takeover of Mindtree, L&T has said that the IT services company will operate as a separate entity, distinct from its existing technology businesses.

“Mindtree will be run as a separate entity, distinct from L&T Infotech (LTI) and L&T Technology Services (LTTS),” L&T CEO and managing director SN Subrahmanyan told CNBC-TV18. “The entities would be run at an arm’s length. It is inappropriate to speculate about the future structure now,” he added.

In one of the major hostile takeovers in corporate India, L&T successfully acquired a controlling stake in Mindtree last month.

“Continuity will be the key theme in the management transition. Mindtree will continue to provide top quality services to its clientele through the committed engagement of the Mindtree minds,” the L&T CEO said.

Following its takeover, the IT firm on Friday said its chief executive officer Rostow Ravanan, chairman Krishnakumar Natarajan and vice-chairman Parthasarathy NS have quit the company.

And Subrahmanyan said Mindtree’s new CEO will be announced in due course.

“No position is ought to be disturbed at Mindtree, and no changes are contemplated right now. There will be a new CEO for Mindtree, the announcement about which will be done in due course.

“Good practices of one company can be adopted by the other. There will be a council formed at an appropriate time in the future, where good ideas can be exchanged. We expect with our engagement, Mindtree, its employees, customers, investors and all associated stakeholders, will benefit in the years to come.

“L&T has been a people-centric company. Run and managed by professionals, the company is focused on good governance and value creation."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved